Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone

[1]  L. Rybicki,et al.  Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia , 2012, Bone Marrow Transplantation.

[2]  V. Roy,et al.  Efficacy and cost‐benefit analysis of risk‐adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization , 2012, Transfusion.

[3]  A. Pickard,et al.  Outcome, toxicity profile and cost analysis of autologous stem cell mobilization , 2011, Bone Marrow Transplantation.

[4]  U. Popat,et al.  Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation , 2011, Transfusion.

[5]  Julie A. Murphy,et al.  Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  R. Stuart,et al.  Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization , 2011, Bone Marrow Transplantation.

[7]  J. Vose,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  H. Goldschmidt,et al.  Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  L. Gordon,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Gertz,et al.  Clinical Impact and Resource Utilization After Stem Cell Mobilization Failure in Patients with Multiple Myeloma and Lymphoma. , 2009 .

[11]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[13]  U. Popat,et al.  Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma , 2009, American journal of hematology.

[14]  Michael L. Wang,et al.  Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  J. Dipersio,et al.  Improving stem cell mobilization strategies: future directions , 2009, Bone Marrow Transplantation.

[16]  P. Ravaud,et al.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Dipersio,et al.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.

[18]  Thomas Fleming,et al.  Red book : pharmacy's fundamental reference , 2004 .

[19]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[20]  I. Petit,et al.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.

[21]  M. Bhatia,et al.  Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[22]  E. Ashihara,et al.  Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. , 2002, Japanese journal of clinical oncology.

[23]  D. Schenkein,et al.  Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. , 2001, Blood.

[24]  E. Gaarsdal,et al.  A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF , 2000, Bone Marrow Transplantation.

[25]  E. Scarpi,et al.  Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma? , 2000, Leukemia & lymphoma.

[26]  T. Lister,et al.  Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. , 2000, The hematology journal : the official journal of the European Haematology Association.

[27]  V. Diehl,et al.  Using at least 5×106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation , 1999, Bone Marrow Transplantation.

[28]  N. Schmitz,et al.  Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Bouabdallah,et al.  Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. , 1996, Journal of hematotherapy.